Latest Pharma Insights
Stock Watch: Core Business Drags As Roche Disappoints And Sanofi Reclassifies
After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on...
Scrip - May 7, 2024
After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on...
Scrip - May 7, 2024
European Progress On Biosimilars Is Just The Beginning
Speaking at Medicines for Europe’s 20th annual biosimilar medicines conference, Isabell Remus, chair of Medicines for Europe’s biosimilar medicines sector...
Generics Bulletin - May 7, 2024
Speaking at Medicines for Europe’s 20th annual biosimilar medicines conference, Isabell Remus, chair of Medicines for Europe’s biosimilar medicines sector...
Generics Bulletin - May 7, 2024
Supply Chain Derisking: The Case For US-India Partnering Amid China Clout
With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the...
Generics Bulletin - May 7, 2024
With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the...
Generics Bulletin - May 7, 2024
Pfizer Takes A Hit On US Oncology Biosimilars In Q1
Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing...
Generics Bulletin - May 7, 2024
Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing...
Generics Bulletin - May 7, 2024
Second Tocilizumab Biosimilar Launches In US
A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just...
Generics Bulletin - May 7, 2024
A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just...
Generics Bulletin - May 7, 2024
AESGP: Despite MDR Failures, ‘Complete Overhaul’ Not Needed
The Association of the European Self-Care Industry gives EU regulators a to-do list of targeted reforms to save the Medical Devices...
HBW Insight - May 7, 2024
The Association of the European Self-Care Industry gives EU regulators a to-do list of targeted reforms to save the Medical Devices...
HBW Insight - May 7, 2024
Hanmi Eyes Digital Healthcare As Next Growth Engine
Hanmi’s head of new product development elucidated the leading Korean pharma firm’s digital healthcare strategy at a recent domestic forum...
Scrip - May 7, 2024
Hanmi’s head of new product development elucidated the leading Korean pharma firm’s digital healthcare strategy at a recent domestic forum...
Scrip - May 7, 2024
Synthetic Biology Matures, Promising Affordable And Personalized Treatments
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
In Vivo - May 7, 2024
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
In Vivo - May 7, 2024
Dealmaking Quarterly Statistics, Q1 2024
During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device...
In Vivo - May 7, 2024
During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device...
In Vivo - May 7, 2024
Winds Of Change Must Blow Through Welsh Health Care – Digital Chief At BioWales 2024
Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social...
In Vivo - May 7, 2024
Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social...
In Vivo - May 7, 2024
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s...
In Vivo - May 7, 2024
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s...
In Vivo - May 7, 2024
Stock Watch: Core Business Drags As Roche Disappoints And Sanofi Reclassifies
After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on...
Scrip - May 7, 2024
After the volatility of pandemic-related sales, investor and analyst attention turned to pharma’s core businesses. With exclusivity losses weighing on...
Scrip - May 7, 2024
Hanmi Eyes Digital Healthcare As Next Growth Engine
Hanmi’s head of new product development elucidated the leading Korean pharma firm’s digital healthcare strategy at a recent domestic forum...
Scrip - May 7, 2024
Hanmi’s head of new product development elucidated the leading Korean pharma firm’s digital healthcare strategy at a recent domestic forum...
Scrip - May 7, 2024
Don’t Stop Manufacturing Because of An Inspection, FDA’s Cavazzoni Says
The FDA drug center director is encouraging manufacturers to contact the agency’s shortage surveillance team before making rash decisions during...
Pink Sheet - May 6, 2024
The FDA drug center director is encouraging manufacturers to contact the agency’s shortage surveillance team before making rash decisions during...
Pink Sheet - May 6, 2024
ORA Chief Says Inspections In Jeopardy Without Additional Funding
The US FDA’s Office of Regulatory Affairs is facing challenges in retaining and hiring new staff, which will impact inspections...
Pink Sheet - May 6, 2024
The US FDA’s Office of Regulatory Affairs is facing challenges in retaining and hiring new staff, which will impact inspections...
Pink Sheet - May 6, 2024
Drug Promotion: Sponsors Are Running Afoul Of US FDA’s CFL Guidance
Recent Office of Prescription Drug Promotion enforcement letters provide several learnings, including the need to be aware of a product’s...
Pink Sheet - May 6, 2024
Recent Office of Prescription Drug Promotion enforcement letters provide several learnings, including the need to be aware of a product’s...
Pink Sheet - May 6, 2024
The Future of ACIP: CDC Vaccine Policy Lead Looks Beyond COVID
The CDC’s Melinda Wharton discusses how the ACIP handled COVID-19 and how the pandemic will shape the committee’s work in...
Pink Sheet - May 6, 2024
The CDC’s Melinda Wharton discusses how the ACIP handled COVID-19 and how the pandemic will shape the committee’s work in...
Pink Sheet - May 6, 2024
Pfizer Finally Wins English Funding For Sickle Cell Drug Oxbryta After Bumpy Ride
After several rejections by NICE and an appeal by Pfizer, the company has reduced the price for its first-in-class sickle...
Pink Sheet - May 6, 2024
After several rejections by NICE and an appeal by Pfizer, the company has reduced the price for its first-in-class sickle...
Pink Sheet - May 6, 2024
Expert Proposes AI Device Reimbursement Model ‘Like Netflix’
Johns Hopkins professor Tinglong Dai says a subscription model for AI is the most sustainable model for reimbursement.
Medtech Insight - May 6, 2024
Johns Hopkins professor Tinglong Dai says a subscription model for AI is the most sustainable model for reimbursement.
Medtech Insight - May 6, 2024
Robotic-Assisted Treatment For Enlarged Prostate Shows Promising Results
A novel robotic-assisted therapy could improve the lives of men with benign prostatic hyperplasia, real-world data presented at the annual...
Medtech Insight - May 6, 2024
A novel robotic-assisted therapy could improve the lives of men with benign prostatic hyperplasia, real-world data presented at the annual...
Medtech Insight - May 6, 2024
GE HealthCare’s New Investigational MRI Promises Advancements On Neurological Disease Research
GE HealthCare announced today a new investigational MRI, which will be used in collaboration with researchers at Boston’s Brigham and...
Medtech Insight - May 6, 2024
GE HealthCare announced today a new investigational MRI, which will be used in collaboration with researchers at Boston’s Brigham and...
Medtech Insight - May 6, 2024
‘Dark Money’ Casts Shadow As Industry, Legislators Push For Litigation-Funding Transparency
AdvaMed is hopeful that legislation at the US federal and state levels will temper third-party litigation funding, which is wreaking...
Medtech Insight - May 6, 2024
AdvaMed is hopeful that legislation at the US federal and state levels will temper third-party litigation funding, which is wreaking...
Medtech Insight - May 6, 2024
AESGP: Despite MDR Failures, ‘Complete Overhaul’ Not Needed
The Association of the European Self-Care Industry gives EU regulators a to-do list of targeted reforms to save the Medical Devices...
HBW Insight - May 7, 2024
The Association of the European Self-Care Industry gives EU regulators a to-do list of targeted reforms to save the Medical Devices...
HBW Insight - May 7, 2024
European Progress On Biosimilars Is Just The Beginning
Speaking at Medicines for Europe’s 20th annual biosimilar medicines conference, Isabell Remus, chair of Medicines for Europe’s biosimilar medicines sector...
Generics Bulletin - May 7, 2024
Speaking at Medicines for Europe’s 20th annual biosimilar medicines conference, Isabell Remus, chair of Medicines for Europe’s biosimilar medicines sector...
Generics Bulletin - May 7, 2024
Supply Chain Derisking: The Case For US-India Partnering Amid China Clout
With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the...
Generics Bulletin - May 7, 2024
With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the...
Generics Bulletin - May 7, 2024
Pfizer Takes A Hit On US Oncology Biosimilars In Q1
Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing...
Generics Bulletin - May 7, 2024
Pfizer has reported US oncology biosimilars sales that were down by 47% in the first quarter of 2024, as pricing...
Generics Bulletin - May 7, 2024
Second Tocilizumab Biosimilar Launches In US
A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just...
Generics Bulletin - May 7, 2024
A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just...
Generics Bulletin - May 7, 2024
Synthetic Biology Matures, Promising Affordable And Personalized Treatments
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
In Vivo - May 7, 2024
Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.
In Vivo - May 7, 2024
Dealmaking Quarterly Statistics, Q1 2024
During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device...
In Vivo - May 7, 2024
During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device...
In Vivo - May 7, 2024
Winds Of Change Must Blow Through Welsh Health Care – Digital Chief At BioWales 2024
Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social...
In Vivo - May 7, 2024
Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social...
In Vivo - May 7, 2024
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s...
In Vivo - May 7, 2024
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s...
In Vivo - May 7, 2024